Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction by Zhu, Mojun, Chen, Chunhua, Foster, Nathan R, Hartley, Christopher, Mounajjed, Taofic, Salomao, Marcela A, Fruth, Briant F, Beamer, Staci E, Kim, Yohan, Harrington, Susan M, Pitot, Henry C, Sanhueza, Cristobal T, Feng, Yening, Herrmann, Joerg, McWilliams, Robert R, Lucien, Fabrice, Huang, Bing Q, Ma, Wen Wee, Bekaii-Saab, Tanios S, Dong, Haidong, Wigle, Dennis, Ahn, Daniel H, Hallemeier, Chris L, Blackmon, Shanda, Yoon, Harry H

Get full text

Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial by Mutter, Robert W, Giri, Sharmila, Fruth, Briant F, Remmes, Nicholas B, Boughey, Judy C, Harless, Christin A, Ruddy, Kathryn J, McGee, Lisa A, Afzal, Arslan, Gao, Robert W, Shumway, Dean A, Vern-Gross, Tamara Z, Villarraga, Hector R, Kenison, Stephanie L, Kang, Yixiu, Wong, William W, Stish, Bradley J, Merrell, Kenneth W, Yan, Elizabeth S, Park, Sean S, Corbin, Kimberly S, Vargas, Carlos E

Get full text

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study by Merchan, Jaime R., Qin, Rui, Pitot, Henry, Picus, Joel, Liu, Glenn, Fitch, Tom, Maples, William J., Flynn, Patrick J., Fruth, Briant F., Erlichman, Charles

Get full text